BR112022004789A2 - Proteínas heterodiméricas - Google Patents

Proteínas heterodiméricas

Info

Publication number
BR112022004789A2
BR112022004789A2 BR112022004789A BR112022004789A BR112022004789A2 BR 112022004789 A2 BR112022004789 A2 BR 112022004789A2 BR 112022004789 A BR112022004789 A BR 112022004789A BR 112022004789 A BR112022004789 A BR 112022004789A BR 112022004789 A2 BR112022004789 A2 BR 112022004789A2
Authority
BR
Brazil
Prior art keywords
heterodimeric proteins
proteins
heterodimeric
multispecific
antibodies
Prior art date
Application number
BR112022004789A
Other languages
English (en)
Portuguese (pt)
Inventor
Sidhartha Chand Dhan
Franciszka Ilkow Veronica
Zahra Jawad
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of BR112022004789A2 publication Critical patent/BR112022004789A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022004789A 2019-09-27 2020-09-28 Proteínas heterodiméricas BR112022004789A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962906918P 2019-09-27 2019-09-27
PCT/US2020/053114 WO2021062382A1 (en) 2019-09-27 2020-09-28 Heterodimeric proteins

Publications (1)

Publication Number Publication Date
BR112022004789A2 true BR112022004789A2 (pt) 2022-06-21

Family

ID=75166489

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004789A BR112022004789A2 (pt) 2019-09-27 2020-09-28 Proteínas heterodiméricas

Country Status (10)

Country Link
US (2) US20210130495A1 (https=)
EP (1) EP4034570A4 (https=)
JP (1) JP7842011B2 (https=)
KR (1) KR20220069935A (https=)
CN (1) CN114787186B (https=)
AU (1) AU2020355253A1 (https=)
BR (1) BR112022004789A2 (https=)
IL (1) IL291618A (https=)
MX (1) MX2022003149A (https=)
WO (1) WO2021062382A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE299938T1 (de) * 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US10689447B2 (en) * 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2843158A1 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
BR112014010580B1 (pt) * 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
ES2876009T3 (es) * 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
MY203000A (en) * 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
KR20200014379A (ko) * 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
CN110028584B (zh) * 2018-01-12 2021-04-06 北京科昕生物科技有限公司 针对egfr蛋白和met蛋白的双特异性抗体
SG11202104136YA (en) * 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins

Also Published As

Publication number Publication date
WO2021062382A1 (en) 2021-04-01
CA3151574A1 (en) 2021-04-01
JP2022549351A (ja) 2022-11-24
US20240360249A1 (en) 2024-10-31
MX2022003149A (es) 2022-04-06
AU2020355253A1 (en) 2022-03-24
EP4034570A4 (en) 2023-10-25
CN114787186B (zh) 2025-06-03
CN114787186A (zh) 2022-07-22
KR20220069935A (ko) 2022-05-27
JP7842011B2 (ja) 2026-04-07
EP4034570A1 (en) 2022-08-03
US20210130495A1 (en) 2021-05-06
IL291618A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
WO2018132739A3 (en) T cell receptors that bind to ny-eso-1 and methods of use thereof
SA521421183B1 (ar) بنيات جسم مضاد لكلودين 18.2 ومجموعة من التمايز 3
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
BR112018074325A2 (pt) anticorpo para ligação a receptor de interleucina 4
ZA201905822B (en) Antibodies against pd-l1
AR115389A1 (es) Anticuerpo antagonista de cd73
BR112019000512A2 (pt) anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
MX2019008803A (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
AR090158A1 (es) Polipeptidos de union a cx3cr1
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
BR112016022055A2 (pt) elementos de ligação ao tnf alfa
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
MX2019014397A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
BR112017018149A2 (pt) célula hospedeira recombinante, método para produzir uma proteína de interesse recombinante, sistema de expressão, e, processos para fabricar uma formulação de proteína estável e para reduzir a atividade de esterase em uma formulação de proteína.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
BR112016017764A2 (pt) anticorpo antidengue de amplo espectro
AR080680A1 (es) Proteinas de union a basigina